Reviewing Intec Pharma Ltd. (NTEC)’s and Zai Lab Limited (NASDAQ:ZLAB)’s results

Both Intec Pharma Ltd. (NASDAQ:NTEC) and Zai Lab Limited (NASDAQ:ZLAB) are Biotechnology companies, competing one another. We will contrast their institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Intec Pharma Ltd. N/A 0.00 43.47M -1.32 0.00
Zai Lab Limited N/A 15387.39 139.07M -2.60 0.00

Table 1 shows the top-line revenue, earnings per share (EPS) and valuation for Intec Pharma Ltd. and Zai Lab Limited.

Profitability

Table 2 provides us the return on equity, return on assets and net margins of both companies.

Net Margins Return on Equity Return on Assets
Intec Pharma Ltd. 0.00% 0% 0%
Zai Lab Limited 0.00% 0% 0%

Institutional & Insider Ownership

The shares of both Intec Pharma Ltd. and Zai Lab Limited are owned by institutional investors at 40.23% and 59.6% respectively. Intec Pharma Ltd.’s share owned by insiders are 16.08%. Insiders Comparatively, owned 35.26% of Zai Lab Limited shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Intec Pharma Ltd. -12.87% -16.85% -33.83% -10.36% 6.67% -29.97%
Zai Lab Limited 2.12% -8.44% 3.69% 68.01% 43.63% 22.35%

For the past year Intec Pharma Ltd. had bearish trend while Zai Lab Limited had bullish trend.

Summary

Zai Lab Limited beats Intec Pharma Ltd. on 3 of the 5 factors.

Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The companyÂ’s lead product candidate is Accordion Pill Carbidopa/Levodopa (AP-CDLD), which is in a Phase III clinical trial for the treatment of ParkinsonÂ’s disease symptoms in advanced ParkinsonÂ’s disease patients. It is also developing Accordion Pill Zaleplon (AP-ZP) that is in a Phase III clinical trial for the treatment of insomnia, including sleep induction and for enhancing of sleep maintenance; Accordion Pill, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and Accordion Pill platform with Cannabidiol and 9-Tetrahydrocannabinol, (AP-CBD/THC), which is in a Phase I clinical trial for the treatment of various indications, including low back neuropathic pain and fibromyalgia. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd. in March 2004. Intec Pharma Ltd. was founded in 2000 and is based in Jerusalem, Israel.

Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics for oncology, and autoimmune and infectious disease therapies in China. Its drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor for the treatment of ovarian, breast, and lung cancers; ZL-2401, an antibiotic for the treatment of acute bacterial skin/skin structure infections, community-acquired bacterial pneumonias, and urinary tract infections; ZL-2301 that is Phase II clinical trial for the treatment of hepatocellular carcinoma; ZL-3101, a novel steroid-sparing topical product that is in Phase II clinical trial for the treatment of eczema and psoriasis; ZL-2302 for the treatment of non-small cell lung cancer; and ZL-1101, an anti-OX40 antagonistic antibody for the treatment of graft-versus-host disease or systemic lupus erythematosus. The company was founded in 2013 and is headquartered in Shanghai, China.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.